35 results about "Peripheral blood specimen" patented technology

The invention discloses probes, primers, a detection system and a kit for detecting mutations of an EGFR gene, and the probes and the primers have the sequences of SEQ ID NO.1 to SEQ ID NO.24. The invention is characterized in that (1), the amplification efficiency is greatly improved to a largest extent; (2) the sensitivity is high, and the detection sensitivity can reach 0.2%; (3) compared with a digital PCR method, operations are simple, the cost is saved, and the clinical application scope is wide; (4) plasma samples with large reaction volume are detected, the DNA sampling quantity of the plasma samples becomes larger, the system is more stable, and the detection rate of the plasma samples is increased; (5) 25 mutations of the EGFR gene can be detected simultaneously in three reaction tubes, and results are intuitive and clear; (6) the detection speed is fast, and consumed time is only 1 / 2 that of the digital PCR; and (7) a detection method can detect peripheral blood samples, has convenient sampling, and can dynamically monitor curative effect of EGFR-TKI drugs on patients.

A method for constructing a systemic lupus erythematosus map model, comprising the following steps: setting a systemic lupus erythematosus group and a normal control group, each group including several peripheral blood samples from different human bodies that have been separated from the human body; The DNA in the blood sample is obtained to obtain the DNA test solution; the DNA content and integrity in the DNA test solution are measured, and if the test is qualified, then the next step is performed; multiplex PCR technology is used to construct a gene library and detect the gene library , if the test is qualified, then proceed to the next step; use high-throughput sequencing technology to sequence the gene library; analyze the sequencing results to construct a systemic lupus erythematosus map model. The construction method of the systemic lupus erythematosus atlas model mentioned above is reasonable and feasible in design, and can effectively obtain SLE-related information as an intermediate result.

A method for screening pathogenic genes with high contribution to rheumatoid arthritis, comprising the following steps: setting a rheumatoid arthritis patient group and a healthy control group, each group including several peripheral blood samples from different human bodies that have been separated from the human body; extracting DNA in peripheral blood samples; prepare the DNA pool of the rheumatoid arthritis patient group and the DNA pool of the healthy control group; measure the content, quality and integrity of the DNA pool, and if it is available, proceed to the next step; construct a DNA library; The genome resequencing method is used to sequence the rheumatoid arthritis patient group and the healthy control group respectively to obtain the sequencing results of the rheumatoid arthritis patient group and the healthy control group; the sequencing results of the rheumatoid arthritis patient group Compared with the sequencing results of the healthy control group, high-contributing gene variation sites were screened out. The above-mentioned screening method can screen out the mutation sites of highly contributing pathogenic genes, which is beneficial to the early treatment and prevention of the inflammation.

The invention discloses a myasthenia gravis detection reagent kit with the combination of non-coded lnc-CXCL1 and a coded gene cxcl1 as a detection or diagnosis screening marker and application. By detecting the expression levels of lnc-CXCL1 and the coded gene cxcl1 in peripheral blood specimens of patients suffering from myasthenia gravis in a relative quantification mode, the reagent kit achieves the effects of screening patients suffering from myasthenia gravis, carrying out QMG on clinical symptoms, and judging hormone therapy.